NASDAQ:NTRP - Neurotrope Stock Price, Forecast & News

$1.29

+0.06 (+4.88 %)

(As of 01/21/2020 11:25 AM ET)

Add

Compare

Today's Range

$1.27

Now: $1.29▼

$1.30

50-Day Range

$0.78

MA: $1.01▼

$1.31

52-Week Range

$0.63

Now: $1.29▼

$8.40

Volume1,105 shs

Average Volume176,832 shs

Market Capitalization$16.86 million

P/E RatioN/A

Dividend YieldN/A

Beta1.98

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:NTRP

Previous Symbol

CUSIPN/A

CIK1513856

Webhttp://www.neurotropebioscience.com/

Phone973-242-0005

Debt

Debt-to-Equity RatioN/A

Current Ratio25.33

Quick Ratio25.33

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.05 per share

Price / Book0.63

Profitability

EPS (Most Recent Fiscal Year)($1.37)

Net Income$-11,020,000.00

Net MarginsN/A

Return on Equity-72.04%

Return on Assets-67.80%

Miscellaneous

Employees6

Outstanding Shares13,070,000

Market Cap$16.86 million

Next Earnings Date3/9/2020 (Estimated)

OptionableOptionable

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

Each week, an exclusive group of investors receives access to a simple list of 3 stocks to put on their radar for the week ahead.

You can sign up today to receive access to next week's watchlist -- generated by a proprietary methodology -- at no cost or obligation.

Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

How were Neurotrope's earnings last quarter?

Neurotrope Inc (NASDAQ:NTRP) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.03. View Neurotrope's Earnings History.

When is Neurotrope's next earnings date?

Neurotrope is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Neurotrope.

What price target have analysts set for NTRP?

2 brokerages have issued 1 year target prices for Neurotrope's shares. Their forecasts range from $1.00 to $16.00. On average, they expect Neurotrope's share price to reach $8.50 in the next year. This suggests a possible upside of 558.9% from the stock's current price. View Analyst Price Targets for Neurotrope.

What is the consensus analysts' recommendation for Neurotrope?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neurotrope.

What are Wall Street analysts saying about Neurotrope stock?

Here are some recent quotes from research analysts about Neurotrope stock:

1. According to Zacks Investment Research, "Neurotrope, Inc. is focused primarily on the development and commercialization of Alzheimer's disease therapeutic products related diagnostics. The Company develops and markets two product platforms, including a non-invasive diagnostic test for Alzheimer's disease and a drug candidate called bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage. Neurotrope, Inc. is based in Plantation, Florida. " (11/1/2019)
2. Maxim Group analysts commented, "Neurotrope announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of Bryostatin-1 in acute lymphoblastic leukemia (ALL)." (2/5/2019)

Has Neurotrope been receiving favorable news coverage?

Press coverage about NTRP stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neurotrope earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Neurotrope.

Are investors shorting Neurotrope?

Neurotrope saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 536,700 shares, a decrease of 7.6% from the December 15th total of 580,600 shares. Based on an average daily trading volume, of 272,500 shares, the short-interest ratio is presently 2.0 days. Approximately 5.5% of the company's stock are short sold. View Neurotrope's Current Options Chain.

Who are some of Neurotrope's key competitors?

Some companies that are related to Neurotrope include Alpine Immune Sciences (ALPN), Kezar Life Sciences (KZR), SCYNEXIS (SCYX), Sunesis Pharmaceuticals (SNSS), American Brivision (Holding) (ABVC), Onconova Therapeutics (ONTX), resTORbio (TORC), DiaMedica Therapeutics (DMAC), Vascular Biogenics (VBLT), Hoth Therapeutics (HOTH), SUMMIT THERAPEU/S (SMMT), Adamis Pharmaceuticals (ADMP), Iterum Therapeutics (ITRM), Zafgen (ZFGN) and Jaguar Health (JAGX).

What other stocks do shareholders of Neurotrope own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Fibrocell Science (FCSC), Neos Therapeutics (NEOS), Alibaba Group (BABA), Pieris Pharmaceuticals (PIRS), Canopy Growth (CGC), Intel (INTC), Iovance Biotherapeutics (IOVA), Adamis Pharmaceuticals (ADMP) and Innovate Biopharmaceuticals (INNT).

Who are Neurotrope's key executives?

Neurotrope's management team includes the folowing people:

Dr. Charles S. Ryan, CEO & Director (Age 55)
Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)
Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)
Dr. Michael Ciraolo, Gen. Counsel & COO (Age 46)
Mr. Jeffrey Benison, Director of Corp. Communications

How do I buy shares of Neurotrope?

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $1.29.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $16.86 million. The company earns $-11,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Neurotrope employs 6 workers across the globe.View Additional Information About Neurotrope.

What is Neurotrope's official website?

The official website for Neurotrope is http://www.neurotropebioscience.com/.

How can I contact Neurotrope?

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]

MarketBeat Community Rating for Neurotrope (NASDAQ NTRP)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		168 (Vote Outperform)
Underperform Votes:		198 (Vote Underperform)
Total Votes:		366

MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/21/2020 by MarketBeat.com Staff

Your Ultimate Investing Toolkit

Just $1.00 for your first month.